How much does a box of 100 mg bosutinib/bosutinib cost?

Bosutinib/Bosutinib is a targeted drug for Philadelphia chromosome-positive chronic myelogenous leukemia (CML). With its clinical application, patients are gradually paying more attention to the price of bosutinib. In particular, the pricing differences of bosutinib in different markets also require patients to comprehensively consider economic factors when making their choice.

Currently, the recommended use of bosutinib is to take it orally once daily with a meal. The tablet must be swallowed whole and should not be broken or cut. For patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase, the recommended starting dose is 400 mg daily; for patients in the chronic phase, accelerated phase or blast phase, or patients with previous drug resistance or intolerance to previous therapy, the recommended starting dose is 500 mg daily.

In China, the original drug of bosutinib has not yet been officially launched, so the relevant market price is still unclear. However, by observing the situation in foreign markets, we can have a preliminary understanding of the price. In places such as Switzerland, Türkiye and Europe, the original drug price of bosutinib is relatively high. Taking the Turkish market as an example, 28 tablets of 500 mg bosutinib are sold for about more than 2,000 yuan. In Switzerland and other European countries, the price may be higher, usually around 40,000 yuan. Such prices put many patients under financial pressure in treatment options.

In addition, some countries provide generic versions of bosutinib. These generic drugs are similar in composition and efficacy to the original drug, but the price is usually significantly lower than the original drug. For example, there is a 100 mg bosutinib generic drug on the Indian market, and the price of 120 tablets may be more than 1,000 yuan. This undoubtedly provides a more affordable option for patients with relatively limited financial conditions. However, when using generic drugs, patients still need to pay attention to the source and quality of the drugs to ensure that the drugs they choose can meet their treatment needs

Reference materials:https://www.cancercareontario.ca/en/drugformulary/drugs/monograph/44371